Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Current Deferred Revenue (2021 - 2024)

Relay Therapeutics (RLAY) has disclosed Current Deferred Revenue for 4 consecutive years, with $7.7 million as the latest value for Q4 2024.

  • On a quarterly basis, Current Deferred Revenue changed N/A to $7.7 million in Q4 2024 year-over-year; TTM through Dec 2024 was $7.7 million, a N/A change, with the full-year FY2024 number at $7.7 million, changed N/A from a year prior.
  • Current Deferred Revenue was $7.7 million for Q4 2024 at Relay Therapeutics, up from $24000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $7.7 million in Q4 2024 to a low of $15000.0 in Q2 2023.
  • A 4-year average of $1.1 million and a median of $207000.0 in 2021 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: crashed 79.95% in 2022, then tumbled 81.93% in 2023.
  • Relay Therapeutics' Current Deferred Revenue stood at $248000.0 in 2021, then plummeted by 66.53% to $83000.0 in 2022, then plummeted by 71.08% to $24000.0 in 2023, then skyrocketed by 31895.83% to $7.7 million in 2024.
  • Per Business Quant, the three most recent readings for RLAY's Current Deferred Revenue are $7.7 million (Q4 2024), $24000.0 (Q3 2023), and $15000.0 (Q2 2023).